Products from BPS Bioscience require a minimum order value above 400€
Background: Anagrelide is a FDA-approved drug for the treatment of essential thrombocythemia. It is originally identified as a potential inhibitor of platelet aggregation. Anagrelide selectively affects thrombocytes while shows no significant effect on white blood cells, erythrocytes, or coagulation. Anagrelide is a potent inotropic agent for dogs with remarkable vasodilatory activity. Additionally, anagrelide can reduce renal blood flow. Furthermore, anagrelide has shown to play roles in other chronic myeloproliferative disorders, such as polycythemia vera, chronic myeloid leukemia and agnogenic myeloid metaplasia. Anagrelide has some side effects involving headache, diarrhea, edema, palpitations, and abdominal pain.
Biological Activity: The exact mechanism by which anagrelide reduces blood platelet count is unclear, although it is known to be a potent inhibitor of PDE3 (IC50 = 36nM).
CAS Number: 58579-51-4
Description: Anagrelide is a selective thrombocytopenic agent that inhibits PDE3. It also has been used in the treatment of chronic myeloid leukemia.
Solubility: Soluble in DMSO (10 mM), water (<1 mg/ml)
Storage Stability: Store at or below -20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day.
Target: PDE3
Biosafety Level: Not applicable (BSL-1)
References: Oertel MD. Am J Health Syst Pharm. 1998 Oct 1;55(19):1979-86.
English
Deutsch
